Skip to main content

ILMN

Stock
Health Care
Diagnostics & Research

Performance overview

ILMN Price
Price Chart

Forward-looking statistics

Beta
0.89
Risk
41.94%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2023 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Company info

SectorHealth Care
IndustryDiagnostics & Research
Employees10K
Market cap$18.1B

Fundamentals

Enterprise value$16.5B
Revenue$4.3B
Revenue per employee—
Profit margin-22.27%
Debt to equity110.09

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$6.08
Dividend per share—
Revenue per share$27.28
Avg trading volume (30 day)$223M
Avg trading volume (10 day)$260M
Put-call ratio—

Macro factor sensitivity

Growth-0.2
Credit+4.6
Liquidity+0.3
Inflation-3.9
Commodities-0.9
Interest Rates-2.2

Valuation

Dividend yield0.00%
PEG Ratio22.81
Price to sales3.68
P/E Ratio22.81
Enterprise Value to Revenue3.80
Price to book6.77

Upcoming events

Next earnings dayMay 9, 2025
Next dividend day—
Ex. dividend day—

News

Illumina Stock: What Went Wrong And Why It's Best To Stay Away

Illumina Inc. ILMN is currently in Phase 17 of its 18-phase Adhishthana Cycle on the weekly chart. A detailed structural analysis using the Adhishthana Principles reveals deeper issues that go beyond short-term price action and offers compelling reasons why this stock should be avoided.

Benzinga (July 17, 2025)
HRMY vs. ILMN: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Harmony Biosciences Holdings, Inc. (HRMY) and Illumina (ILMN). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research (July 15, 2025)
Illumina Stock May Benefit From New Agreement to Acquire SomaLogic

ILMN jumps 2.9% after striking a $350M deal to acquire SomaLogic and boost its fast-growing multiomics strategy.

Zacks Investment Research (June 26, 2025)
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI

Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.

CNBC Television (May 28, 2025)
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%

Carl Icahn is making bold moves from the lab to the tarmac.

Benzinga (May 16, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free